Advanced search
Publication Cover
Modern Rheumatology Volume 18, 2008 - Issue 2
Journal homepage
43
Views
45
CrossRef citations to date
0
Altmetric
Original Article

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

Yoshiya TanakaThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, JapanCorrespondence[email protected]
,
Tsutomu TakeuchiDivision of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
,
Eisuke InoueInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Kazuyoshi SaitoThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan
,
Naoya SekiguchiDivision of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
,
Eri SatoInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Masao NawataThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan
,
Hideto KamedaDivision of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
,
Shigeru IwataThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan
,
Kouichi AmanoDivision of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
&
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
 show all
Pages 146-152 | Received 21 Sep 2007, Accepted 31 Oct 2007, Published online: 02 Jan 2014

References

  • Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.
  • Weaver AL. Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol. 2004;14:101–12.
  • American College of Rheumatology Subcommittee on Rheuma-toid Arthritis. Guidelines for the management of rheumatoid arthritis, 2002 update. Arthritis Rheum 2002;46:328–46.
  • Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34–45.
  • Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007 ;370(9602) : 1861–74.
  • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999;354:1932–9.
  • Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breed-veld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.
  • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051–65.
  • Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheu-matoid arthritis patients who had no clinical improvement-a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020–30.
  • Smolen JS, van Der Heijde DM, St Clair EW, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54:702–10.
  • Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis manage-ment group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28–32.
  • Miyasaka N, Takeuchi T, Eguchi K. Offi cial Japanese Guidelines for the use of infl iximab for rheumatoid arthritis. Modern Rheum. 2005;15:4–8.
  • Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Com-parison of DA528-ESR and DA528-CRP on threshold values. Ann Rheum Dis. 2007;66: 407–9.
  • Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(2):189–94.
  • Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005;64:1274–9.
  • Wendling D, Mateme GE, Michel F, Lohse A, Lehuede G, Toussirot E, Massol J, Woronoff-Lemsi MC. Infliximab contin-uation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine. 2005;72:309–12.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.